Table 1 Characteristics of 28 included studies in the systematic review and meta-analysis.
Study | Country | Disease | Age, y | Study Design | Diagnostic Method | Outcome | Depression Prevalence (case/participant) | NOS |
|---|---|---|---|---|---|---|---|---|
Kong, X.11 | China | Glaucoma | Mean (SD) 55.5 (NR) | Cross-sectional study | SDS | ≥50 | 48% (48/100) | 2 |
Hallak, J. A.13 | US | DED | Mean (SD) 52.6 (16.2) | Cross-sectional study | BDI | >9 | 38% (19/50) | 3 |
Van der Aa, H. P.14 | Netherland | Eye disease | Mean (SD) 77.6 (9.3) | Cross-sectional study | CES-D | ≥16 | 5% (33/615) | 3 |
Ayaki, M.10 | Japan | Eye disease | Mean (SD) 59.5 (19.9) | Descriptive study | HADS | ≥10 | 45% (332/730) | 3 |
Vehof J.34 | British | DED | Mean (SD) 57.1 (13.1) | Cross-sectional study (population-based) | Clinical diagnosis | NR | 17% (64/367) | 3 |
Labbé A35 | China | DED | Mean (SD) 67.3 (9.6) | Cross-sectional study (population-based) | SDS | ≥40 | 14% (33/241) | 3 |
Eramudugolla, R.15 | Australia | Age-related eye disease | Mean (range) NR (>70) | Cross-sectional study (population-based) | GADS | NR | 7% (20/287) | 1 |
Agorastos, A.16 | Germany | Glaucoma | Mean (range) NR (>50) | Descriptive study | BDI-II | ≥10 | 36% (31/86) | 3 |
Jivraj, J.17 | Canada | AMD | Mean (range) NR (>50) | Descriptive study | CES-D | ≥16 | 21% (20/94) | 4 |
Richards, H. S.18 | UK | Ptosis | Mean (SD) 61.6 (15.3) | Descriptive study | HADS | >10 | 11% (6/57) | 2 |
Kim, S.19 | Korea | RP | Mean (SD) 40.1 (11.0) | Cross-sectional study (population-based) | NR | NR | 35% (65/187) | 1 |
Lee, W. J.20 | Korea | AMD | Mean (SD) 55 (NR) | Descriptive study | GDS | ≥5 | 26% (28/107) | 3 |
Zhou, C.21 | China | Glaucoma | Mean (SD) 55.4 (15.3) | Descriptive study | HADS | >10 | 16% (83/506) | 3 |
Qian, Y.8 | US | Ocular inflammation | Mean (range) NR (>18) | Descriptive study | BDI | >13 | 27% (28/104) | 2 |
Popescu, M. L.22 | Canada | Eye disease | Mean (range) NR (>65) | Cross-sectional study | GDS-15 | ≥5 | 31% (71/227) | 4 |
Yochim, B. P.23 | US | Glaucoma | Mean (SD) 70 (9.2) | Descriptive study | GDS | ≥5 | 12% (5/41) | 3 |
Wang, S. Y.24 | US | Glaucoma | Mean (SD) 66.9 (1.03) | Cross-sectional study (population-based) | PHQ-9 | ≥10 | 11% (49/453) | 4 |
Kim, K. W.12 | Korea | DED | Mean (SD) 71. 9 (5.8) | Cross-sectional study (population-based) | SGDS-K | NR | 33% (66/198) | 1 |
Amaro, T. A.25 | US | Uveal melanoma | Mean (range) 52 (29–80) | Descriptive study | BDI | >11 | 45% (9/20) | 3 |
Tastan, S.26 | Turkey | Glaucoma | Mean (SD) 64.2 (13.2) | Cross-sectional study | HADS | ≥8 | 57% (69/121) | 4 |
Freeman, E. E.27 | Canada | Cataract | Mean (range) NR (>45) | Descriptive study | GDS-30 | ≥10 | 26% (174/657) | 2 |
Banerjee, A.28 | US | AMD | Mean (range) NR (>50) | Descriptive study | GDS | >4 | 26% (14/53) | 3 |
Mabuchi, F.29 | Japan | Glaucoma | Mean (SD) 66.9 (12.1) | Cross-sectional study | HADS | >10 | 11% (25/230) | 3 |
Skalicky, S.30 | Australia | Glaucoma | Mean (range) NR (70–90) | Descriptive study | GDS-15 | >4 | 19% (25/131) | 3 |
Augustin, A.7 | France Germany Italy | AMD | Mean (SD) 77 (NR) | Descriptive study | HADS | ≥11 | 18% (60/336) | 4 |
Sun, C.31 | Australia | AMD | Mean (range) NR (69–97) | Cross-sectional study | CES-D | ≥10 | 16% (58/367) | 3 |
Cumurcu, T.32 | Turkey | Glaucoma | Mean (range) NR (30–80) | Cross-sectional study | HDRS | NR | 25% (18/73) | 4 |
Brody, B. L.33 | US | AMD | Mean (SD) 80 (NR) | Descriptive study | DSM | DSM-IV criteria | 32% (49/151) | 1 |
Total | \ | \ | \ | \ | \ | 25% (1502/6589) | \ |
